Aripiprazole (Standard)

Aripiprazole (Standard) is the analytical standard of Aripiprazole. This product is intended for research and analytical applications. Aripiprazole (OPC-14597), an atypical antipsychotic, is a potent and high-affinity dopamine D2 receptor partial agonist. Aripiprazole is an inverse agonist at 5-HT2B and 5-HT2A receptors and displays partial agonist actions at 5-HT1A, 5-HT2C, D3, and D4 receptors. Aripiprazole can be used for the research of schizophrenia and COVID19[1][2][3][4].

Product Specifications

CAS Number

[129722-12-9]

Product Name Alternative

OPC-14597 (Standard)

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335-H413

Target

5-HT Receptor; Dopamine Receptor; Reference Standards

Type

Reference Standards

Related Pathways

GPCR/G Protein; Neuronal Signaling; Others

Field of Research

Infection; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/aripiprazole-standard.html

Smiles

O=C1NC2=C(C=CC(OCCCCN3CCN(C4=CC=CC(Cl)=C4Cl)CC3)=C2)CC1

Molecular Formula

C23H27Cl2N3O2

Molecular Weight

448.39

Precautions

P261-P264-P270-P271-P273-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Stip E, et al. Aripiprazole in schizophrenia and schizoaffective disorder: A review. Clin Ther. 2010;32 Suppl 1:S3-20.|[2]Burris KD, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002 Jul;302 (1) :381-9.|[3]Davies MA, et al. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 2004 Winter;10 (4) :317-36.|[4]Crespo-Facorro B, et al. Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis. Front Pharmacol. 2021 Mar 2;12:646701.|[5]Russo E, et al. Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. Neuropharmacology. 2013 Jan;64:371-9.